{"id":11238,"date":"2019-11-19T00:00:00","date_gmt":"2019-11-19T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/"},"modified":"2025-08-19T08:28:20","modified_gmt":"2025-08-19T13:28:20","slug":"approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/","title":{"rendered":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE"},"content":{"rendered":"<p>Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9&nbsp;Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&rsquo;une \u00e9valuation prioritaire, DARZALEX<sup>\u00ae<\/sup>&nbsp;(daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone&nbsp;(Rd) pour le traitement des patients atteints d&rsquo;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches&nbsp;(GACS). L&rsquo;approbation se fonde sur les r\u00e9sultats de l&rsquo;\u00e9tude clinique de phase&nbsp;III&nbsp;MAIA, publi\u00e9e dans la revue&nbsp;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=fr&amp;o=2625779-1&amp;h=686767432&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1817249&amp;a=New%C2%A0England+Journal+of%C2%A0Medicine\" target=\"_blank\" rel=\"noopener\"><em>New&nbsp;England Journal of&nbsp;Medicine<\/em><\/a>; ceux-ci ont montr\u00e9 que l&rsquo;association DARZALEX<sup>\u00ae<\/sup>-Rd a r\u00e9duit le risque de progression de la maladie ou de d\u00e9c\u00e8s comparativement au traitement par le sch\u00e9ma&nbsp;Rd seul (r\u00e9duction du risque de 44&nbsp;%).<\/p>\n<p><a href=\"https:\/\/www.newswire.ca\/fr\/news-releases\/janssen-annonce-l-approbation-par-sante-canada-de-darzalex-r-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-le-traitement-des-patients-atteints-d-un-myelome-multiple-nouvellement-diagnostique-non-admissibles-a-une--894883253.html\" target=\"_blank\" rel=\"noopener\">Lire la suite<\/a>&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9&nbsp;Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&rsquo;une \u00e9valuation prioritaire, DARZALEX\u00ae&nbsp;(daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone&nbsp;(Rd) pour le traitement des patients atteints d&rsquo;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches&nbsp;(GACS). L&rsquo;approbation se fonde sur [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11238","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&#039;une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d&#039;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L&#039;approbation se fonde sur\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&#039;une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d&#039;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L&#039;approbation se fonde sur\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-11-19T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:20+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&#039;une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d&#039;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L&#039;approbation se fonde sur\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#blogposting\",\"name\":\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\\u00c9NALIDOMIDE ET LA DEXAM\\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\\u00c9 NON ADMISSIBLES \\u00c0 UNE GREFFE | My\\u00e9lome Canada\",\"headline\":\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\\u00c9NALIDOMIDE ET LA DEXAM\\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\\u00c9 NON ADMISSIBLES \\u00c0 UNE GREFFE\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2019-11-19T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:20-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#listItem\",\"name\":\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\\u00c9NALIDOMIDE ET LA DEXAM\\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\\u00c9 NON ADMISSIBLES \\u00c0 UNE GREFFE\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#listItem\",\"position\":4,\"name\":\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\\u00c9NALIDOMIDE ET LA DEXAM\\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\\u00c9 NON ADMISSIBLES \\u00c0 UNE GREFFE\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/\",\"name\":\"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\\u00c9NALIDOMIDE ET LA DEXAM\\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\\u00c9 NON ADMISSIBLES \\u00c0 UNE GREFFE | My\\u00e9lome Canada\",\"description\":\"Le groupe Janssen Pharmaceutical Companies of Johnson & Johnson a annonc\\u00e9 que Sant\\u00e9 Canada a r\\u00e9cemment approuv\\u00e9, \\u00e0 la suite d'une \\u00e9valuation prioritaire, DARZALEX\\u00ae (daratumumab) en association avec le l\\u00e9nalidomide et la dexam\\u00e9thasone (Rd) pour le traitement des patients atteints d'un my\\u00e9lome multiple nouvellement diagnostiqu\\u00e9 non admissibles \\u00e0 une greffe autologue de cellules souches (GACS). L'approbation se fonde sur\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/11\\\/19\\\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2019-11-19T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:20-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada","description":"Le groupe Janssen Pharmaceutical Companies of Johnson & Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d'une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d'un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L'approbation se fonde sur","canonical_url":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#blogposting","name":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada","headline":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2019-11-19T00:00:00-05:00","dateModified":"2025-08-19T08:28:20-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#listItem","name":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#listItem","position":4,"name":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/","name":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada","description":"Le groupe Janssen Pharmaceutical Companies of Johnson & Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d'une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d'un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L'approbation se fonde sur","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2019-11-19T00:00:00-05:00","dateModified":"2025-08-19T08:28:20-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada","og:description":"Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d'une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d'un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L'approbation se fonde sur","og:url":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/","article:published_time":"2019-11-19T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:20+00:00","twitter:card":"summary_large_image","twitter:title":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE | My\u00e9lome Canada","twitter:description":"Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9 Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d'une \u00e9valuation prioritaire, DARZALEX\u00ae (daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (Rd) pour le traitement des patients atteints d'un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches (GACS). L'approbation se fonde sur"},"aioseo_meta_data":{"post_id":"11238","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:03:46","updated":"2026-04-30 07:27:58","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11238"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238\/revisions"}],"predecessor-version":[{"id":31321,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238\/revisions\/31321"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}